First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. - Wikidata - wikimedia - TriplyDB

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

http://www.wikidata.org/entity/Q34426777

about

Applications of 211At and 223Ra in targeted alpha-particle radiotherapy Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 Therapeutic radionuclides in nuclear medicine: current and future prospects Targeting bone physiology for the treatment of metastatic prostate cancer Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Radioimmunotherapy of human tumours Samarium for osteoblastic bone metastases and osteosarcoma The elements of life and medicines Radium-223 dichloride in clinical practice: a review.Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease Astatine Radiopharmaceuticals: Prospects and Problems Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets Systemic targeted alpha radiotherapy for cancer.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis Targeted alpha anticancer therapies: update and future prospects In vivo molecular targeted radiotherapy.Real-time scintigraphic assessment of intravenous radium-223 administration for quality control Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.Radium-223 for the treatment of castration-resistant prostate cancer.Cancer-targeted therapies and radiopharmaceuticals Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer.Molecular targeted α-particle therapy for oncologic applications.Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.

P2860

Q24610016-1245BB22-AF1E-4A57-937C-FF9797A81CA4 Q24629826-81CE5E98-09B5-4533-A669-BA029D35D0AA Q26740064-EDCA839B-3D8C-49D5-B93B-17CE59AF1214 Q26752785-E2D4102A-64AF-4F5E-AFF6-EF0598028348 Q26823733-C01932D2-1875-4119-9D69-7FFBDFDBE917 Q26861575-BA7ED43D-156B-4C65-86BE-98B695FDCDA6 Q26861998-C81A46E0-A722-40E2-8E79-B910CF54D574 Q26863249-6D12B689-CA6F-412A-8C62-1A75482F7128 Q28077633-A77E4AF5-A4F1-42A7-9CD4-ED032BBA927E Q28079918-1D022648-2004-4DED-A1DA-4E1A73E25D69 Q28088825-DEE258F6-02E0-4623-B45A-8DB96518479D Q28253337-B405A16A-EBD7-42FE-90B9-6CE3DCDBF040 Q28649323-34FC4E88-7FB4-4683-9E4D-1EF35CC024F4 Q30251496-149837A8-F31C-4355-9196-AE1DC99C1CB8 Q30439259-BA743D0D-BC8D-4524-8025-9F75D03FAD34 Q30852837-B285128E-FE96-4A8C-A3B5-2E98BB91698A Q33405335-7D12B9F0-FF39-44E8-AB33-48600EF86477 Q33437726-41E07E35-5BA0-4D0B-ADD0-8DC85042BF52 Q33628466-3C851206-9AC5-487F-8193-711892D73655 Q33640550-C0C577A3-4BA6-47C8-96B2-A9634921E09E Q33705446-AD628907-76C9-4C74-9DA0-6CBF5B463E51 Q33789188-0E94C720-CF11-43D9-90C7-DE7A11BFA34D Q33942600-B88987D5-A5B9-4CB7-B1DA-6013B4208F1E Q34023510-9F1CE66D-493F-47AD-B6F5-7CCE84F3FB8D Q34023663-6109B3C3-30AC-497D-BA17-75A2134528B0 Q34377594-63FC96C0-569A-4DC6-AC86-AEFC36B6D158 Q34448130-FF09972F-A920-4D8F-B0AC-0D117A526864 Q34511439-50E27ED8-0930-49CF-9C67-4B5EC8D6F99F Q34991297-03BE4EFD-6E1C-45D9-B888-9F8E99CEEBD4 Q35144135-0B773DA7-3807-4D85-8F22-9AC1FB24A250 Q35623683-0C294725-C7C4-4EBF-BEE6-052D48E5ED48 Q35650472-651B82B5-DCFA-46D6-9F7D-395BC60DEDC1 Q35653986-E9DF72D4-F5F2-4080-ABF8-39CD01F0B5DB Q35683440-FF1AA905-015E-4EB2-BA78-67406D8471DF Q35743202-6A7936AB-8C79-448E-93E8-89AE39D23641 Q35814989-A1B1E362-EC06-4DC4-A5E8-35350FD5E4AB Q36335307-BB62A7FF-7947-42A1-87E5-815F0C99D1E6 Q36507013-BFD99ED3-AF89-4DE5-B352-BBB065672851 Q36597347-157C89A9-5579-4E8E-88EB-A0B92B3D21A8 Q36817119-8A4C6132-9FA6-4784-B437-A499F4DDAC9D

P2860

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

http://www.wikidata.org/entity/Q34426777

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

First clinical experience with ...... atment of skeletal metastases.

@ast

First clinical experience with ...... atment of skeletal metastases.

@en

First clinical experience with ...... atment of skeletal metastases.

@nl

type

label

First clinical experience with ...... atment of skeletal metastases.

@ast

First clinical experience with ...... atment of skeletal metastases.

@en

First clinical experience with ...... atment of skeletal metastases.

@nl

prefLabel

First clinical experience with ...... atment of skeletal metastases.

@ast

First clinical experience with ...... atment of skeletal metastases.

@en

First clinical experience with ...... atment of skeletal metastases.

@nl

P1433

Q34426777-70485DB3-3888-4F65-8871-15F14D524857

P1476

Q34426777-4E5E9759-C049-45D7-80A0-829F160DE8DA

P2093

Q34426777-236CE7E4-3506-4D89-B560-CDF6A546C864

Q34426777-4BB9D9A7-027F-4142-B4DB-DF510B7D0CC8

Q34426777-674A5187-B02D-4CDE-9160-C0416F25F338

Q34426777-7ECEA476-31E2-451C-A461-F48A2CD609ED

Q34426777-A18F72A8-EF69-4BA4-A63F-D7CE6C276A17

Q34426777-C12AA29A-2242-4C3B-8D2B-5897C78B3DE6

P304

Q34426777-302625B9-E1B4-419B-870D-04B7105BA4E6

P31

Q34426777-10957318-329F-422D-B459-3256D1B17242

P356

Q34426777-8BB7E477-4013-45F0-A5EF-171651B57EFD

P407

Q34426777-5F326E21-9D1F-4BE3-8E3D-239F49B6BD93

P433

Q34426777-D69BD397-06E3-4541-9A84-48A14F56271E

P478

Q34426777-D2683752-7291-4C06-8326-C5DC19D9AC71

P50

Q34426777-7ECDD78F-CC6C-431E-9443-544CF369D5A0

Q34426777-7F794D9E-D390-4A24-B8A5-B09A32A72068

P577

Q34426777-A8E9E8E1-0894-49FA-91BA-F5BA57864FCF

P5875

Q34426777-F21C1C34-5935-48D4-8596-5C949C3B74B5

P698

Q34426777-64016273-B825-45C1-8A49-6A3007222DFB

P356

1078-0432.CCR-04-2244

P1433

Clinical Cancer Research

P1476

First clinical experience with ...... atment of skeletal metastases.

@en

P2093

Gro Salberg

http://www.w3.org/2001/XMLSchema#string

Jan-Erik Westlin

http://www.w3.org/2001/XMLSchema#string

Kari W Borch

http://www.w3.org/2001/XMLSchema#string

Lise Balteskard

http://www.w3.org/2001/XMLSchema#string

Roy H Larsen

http://www.w3.org/2001/XMLSchema#string

Sten Nilsson

http://www.w3.org/2001/XMLSchema#string

P304

4451-4459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-04-2244

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Sophie D. Fosså

Øyvind Sverre Bruland

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7783925

http://www.w3.org/2001/XMLSchema#string

P698

15958630

http://www.w3.org/2001/XMLSchema#string